Dasatinib (Sprycel®), a second-generation TKI, has been shown to be effective as an
anticancer drug in the treatment of patients with chronic myeloid leukemia or Philadelphia
chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to
imatinib. Several methods of gefitinib synthesis are included in this review. UV spectroscopy
of dasatinib showed a λ max of approximately 320–330 nm, and IR spectroscopy principal
peaks were observed at 3418 (Nsingle bondH), 3200 (Osingle bondH), 1620 (Cdouble …